Andrew Tang

FY17 reporting season kicks off in earnest mid-August and according to the latest IBES consensus earnings estimates, EPS growth for the S&P/ASX200 is forecast at 13% in FY17, slightly down from 13.6% at the end of 1H17. Pleasingly this would still mark the end of the earnings recession after two... Show More

Scott Power

Admedus has had an interesting couple of months including the completion of a successful capital raising. The company has three business divisions, however, in this interview we focus specifically on the tissue regenerative medicines business. The lead product in this business is called Cardiocell and we ask Lee to share... Show More